Potential role of MEK inhibition in treating patients with colorectal cancer

Paul Brittain, S Gail Eckhardt, Christopher H. Lieu

Research output: Contribution to journalReview article

Abstract

The mitogen-activated protein kinase (MAPK) signaling pathway plays a fundamental role in the carcinogene-sis of colorectal and numerous other neoplasms. The development of targeted agents that inhibit MEK 1 and 2 has created the potential for downstream blockade of the MAPK pathway. Though MEK inhibition has demonstrated clinically significant efficacy in several tumor types, therapeutic success has been limited in colorectal cancer (CRC). This review will describe the current experience with MEK inhibition. It will also highlight ongoing efforts and future directions, including potential rational combination strategies and the investigation into potential predictive biomarkers of response.

Original languageEnglish (US)
Pages (from-to)34-38
Number of pages5
JournalCurrent Cancer Therapy Reviews
Volume10
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Colorectal Neoplasms
Mitogen-Activated Protein Kinases
Neoplasms
Biomarkers
Therapeutics

Keywords

  • Colorectal cancer
  • MAPK pathway
  • MEK inhibitor
  • Targeted therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

Potential role of MEK inhibition in treating patients with colorectal cancer. / Brittain, Paul; Eckhardt, S Gail; Lieu, Christopher H.

In: Current Cancer Therapy Reviews, Vol. 10, No. 1, 01.01.2014, p. 34-38.

Research output: Contribution to journalReview article

@article{f7a42622ed1b45eeb7d4c5ff3815e4ed,
title = "Potential role of MEK inhibition in treating patients with colorectal cancer",
abstract = "The mitogen-activated protein kinase (MAPK) signaling pathway plays a fundamental role in the carcinogene-sis of colorectal and numerous other neoplasms. The development of targeted agents that inhibit MEK 1 and 2 has created the potential for downstream blockade of the MAPK pathway. Though MEK inhibition has demonstrated clinically significant efficacy in several tumor types, therapeutic success has been limited in colorectal cancer (CRC). This review will describe the current experience with MEK inhibition. It will also highlight ongoing efforts and future directions, including potential rational combination strategies and the investigation into potential predictive biomarkers of response.",
keywords = "Colorectal cancer, MAPK pathway, MEK inhibitor, Targeted therapy",
author = "Paul Brittain and Eckhardt, {S Gail} and Lieu, {Christopher H.}",
year = "2014",
month = "1",
day = "1",
doi = "10.2174/157339471001140815152055",
language = "English (US)",
volume = "10",
pages = "34--38",
journal = "Current Cancer Therapy Reviews",
issn = "1573-3947",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Potential role of MEK inhibition in treating patients with colorectal cancer

AU - Brittain, Paul

AU - Eckhardt, S Gail

AU - Lieu, Christopher H.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The mitogen-activated protein kinase (MAPK) signaling pathway plays a fundamental role in the carcinogene-sis of colorectal and numerous other neoplasms. The development of targeted agents that inhibit MEK 1 and 2 has created the potential for downstream blockade of the MAPK pathway. Though MEK inhibition has demonstrated clinically significant efficacy in several tumor types, therapeutic success has been limited in colorectal cancer (CRC). This review will describe the current experience with MEK inhibition. It will also highlight ongoing efforts and future directions, including potential rational combination strategies and the investigation into potential predictive biomarkers of response.

AB - The mitogen-activated protein kinase (MAPK) signaling pathway plays a fundamental role in the carcinogene-sis of colorectal and numerous other neoplasms. The development of targeted agents that inhibit MEK 1 and 2 has created the potential for downstream blockade of the MAPK pathway. Though MEK inhibition has demonstrated clinically significant efficacy in several tumor types, therapeutic success has been limited in colorectal cancer (CRC). This review will describe the current experience with MEK inhibition. It will also highlight ongoing efforts and future directions, including potential rational combination strategies and the investigation into potential predictive biomarkers of response.

KW - Colorectal cancer

KW - MAPK pathway

KW - MEK inhibitor

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84906904335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906904335&partnerID=8YFLogxK

U2 - 10.2174/157339471001140815152055

DO - 10.2174/157339471001140815152055

M3 - Review article

AN - SCOPUS:84906904335

VL - 10

SP - 34

EP - 38

JO - Current Cancer Therapy Reviews

JF - Current Cancer Therapy Reviews

SN - 1573-3947

IS - 1

ER -